{"filing":{"accession_number":"0001213900-26-081559","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-07-27","report_date":"2026-07-27","primary_document":"ea0299286-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026081559/ea0299286-6k_radiopharm.htm"},"events":[{"id":20580,"run_id":18524,"accession_number":"0001213900-26-081559","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The press release announces a concurrent registered direct offering of 1,281,646 ADSs (384.5 million ordinary shares) at US$3.16 per ADS raising approximately US$4.1 million, plus unregistered warrants and an Australian private placement and share purchase plan raising up to A$12.7 million (US$8.9 million). This is a material dilutive equity issuance totaling approximately US$12.9 million in gross proceeds, typical of capital-raising activity by clinical-stage biopharmaceutical companies and clearly material to investors assessing ownership dilution and cash position.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-27","form":"6-K","submitted_at":null,"items":[{"id":19989,"accession_number":"0001213900-26-081559","item_number":"EX-99.1","item_title":"ea029928601ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The press release announces a concurrent registered direct offering of 1,281,646 ADSs (384.5 million ordinary shares) at US$3.16 per ADS raising approximately US$4.1 million, plus unregistered warrants and an Australian private placement and share purchase plan raising up to A$12.7 million (US$8.9 million). This is a material dilutive equity issuance totaling approximately US$12.9 million in gross proceeds, typical of capital-raising activity by clinical-stage biopharmaceutical companies and clearly material to investors assessing ownership dilution and cash position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:08:19.914763+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19989,"accession_number":"0001213900-26-081559","item_number":"EX-99.1","item_title":"ea029928601ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The press release announces a concurrent registered direct offering of 1,281,646 ADSs (384.5 million ordinary shares) at US$3.16 per ADS raising approximately US$4.1 million, plus unregistered warrants and an Australian private placement and share purchase plan raising up to A$12.7 million (US$8.9 million). This is a material dilutive equity issuance totaling approximately US$12.9 million in gross proceeds, typical of capital-raising activity by clinical-stage biopharmaceutical companies and clearly material to investors assessing ownership dilution and cash position.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-27T10:08:19.914763+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-27"}]}